Pleiotropic effects of statins: The role of eicosanoid production

Current Atherosclerosis Reports

Volumn 14, Issue 2, 2012, Pages 135-139

  Birnbaum, Yochai ^a,b,c   Ye, Yumei ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

^c ST LUKE S EPISCOPAL HOSPITAL   (United States)

Author keywords

5 lipooxygenase; Arachidonic acid; Aspirin; Cyclooxygenase 2; Eicosanoids; Inflammation; LDL cholesterol; Pleiotropic effects; Prostacyclin; Protein kinase A (PKA); Statins

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; ARACHIDONATE 5 LIPOXYGENASE; ATORVASTATIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLOOXYGENASE 2; CYTOSOLIC PHOSPHOLIPASE A2; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSANOID; LEUKOTRIENE; LIPOXIN A; PROSTACYCLIN; SIMVASTATIN;

ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROTIC PLAQUE; CYTOKINE PRODUCTION; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DYSLIPIDEMIA; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME MECHANISM; ENZYME PHOSPHORYLATION; HUMAN; HYPERPLASIA; LOW DRUG DOSE; MOLECULAR INTERACTION; NEOINTIMA; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; NONHUMAN; PLEIOTROPY; REVIEW; UPREGULATION;

ANIMALS; ARACHIDONATE 5-LIPOXYGENASE; CHOLESTEROL, LDL; CYCLIC AMP-DEPENDENT PROTEIN KINASES; CYCLOOXYGENASE 2; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EICOSANOIDS; GENETIC PLEIOTROPY; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; LIPID METABOLISM; PHOSPHORYLATION; RATS; SENSITIVITY AND SPECIFICITY;

EID: 84861230309     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-012-0232-5     Document Type: Review

References (27)

1. Wang CY, Liu PY, Liao JK. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med. 2008;14:37-44.
2. Gotto Jr AM. The cardiology patient page. Statins: powerful drugs for lowering cholesterol: advice for patients. Circulation. 2002;105:1514-6. (Pubitemid 34297619)
3. Iida K, Goland S, Akima T, et al. Effect of a single 20-mg tablet of Atorvastatin on brachial artery blood flow in normolipidemic male smokers versus nonsmokers. Am J Cardiol. 2007;100:881-4. (Pubitemid 47268283)
4. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature. 1990;343:425-30.
5. Van Aelst L, D'Souza-Schorey C. Rho GTPases and signaling networks. Genes Dev. 1997;11:2295-322. (Pubitemid 27408529)
6. Bocan TM, Mazur MJ, Mueller SB, et al. Antiatherosclerotic activity of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase in cholesterol-fed rabbits: a biochemical and morphological evaluation. Atherosclerosis. 1994;111:127-42. (Pubitemid 24330624)
7. Atar S, Ye Y, Lin Y, et al. Atorvastatin-induced cardioprotection is mediated by increasing inducible nitric oxide synthase and consequent S-nitrosylation of cyclooxygenase-2. Am J Physiol. 2006;290:H1960-1968.
8. Birnbaum Y, Lin Y, Ye Y, et al. Aspirin before reperfusion blunts the infarct size limiting effect of atorvastatin. Am J Physiol. 2007;292:H2891-2897. (Pubitemid 47084538)
9. Birnbaum Y, Ye Y, Lin Y, et al. Aspirin augments 15-epi-lipoxin A4 production by lipopolysaccharide, but blocks the pioglitazone and atorvastatin induction of 15-epi-lipoxin A4 in the rat heart. Prostag Other Lipid Mediat. 2007;83:89-98. (Pubitemid 46151755)
10. Birnbaum Y, Ye Y, Rosanio S, et al. Prostaglandins mediate the cardioprotective effects of atorvastatin against ischemiareperfusion injury. Cardiovasc Res. 2005;65:345-55. (Pubitemid 40082476)
11. Ye Y, Lin Y, Atar S, et al. Myocardial protection by pioglitazone, atorvastatin, and their combination: mechanisms and possible interactions. Am J Physiol. 2006;291:H1158-1169. (Pubitemid 44343659)
12. Ye Y, Nishi SP, Manickavasagam S, et al. Activation of peroxisome proliferator-activated receptor-gamma (PPAR-gamma) by atorvastatin is mediated by 15-deoxy-delta-12,14-PGJ2. Prostag Other Lipid Mediat. 2007;84:43-53. (Pubitemid 47069933)
13. Ye Y, Lin Y, Perez-Polo JR, et al. Phosphorylation of 5-lipoxygenase at ser523 by protein kinase A determines whether pioglitazone and atorvastatin induce proinflammatory leukotriene B4 or anti-inflammatory 15-epi-lipoxin a4 production. J Immunol. 2008;181:3515-23.
14. Birnbaum Y, Ye Y, Lin Y, et al. Augmentation of myocardial production of 15-epi-lipoxin-a4 by pioglitazone and atorvastatin in the rat. Circulation. 2006;114:929-35. (Pubitemid 44337136)
15. Planaguma A, Pfeffer MA, Rubin G, et al. Lovastatin decreases acute mucosal inflammation via 15-epi-lipoxin A4. Mucosal Immunol. 2010;3:270-9.
16. Spite M, Serhan CN. Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins. Circ Res. 2010;107:1170-84.
17. Serhan CN, Chiang N. Novel endogenous small molecules as the checkpoint controllers in inflammation and resolution: entree for resoleomics. Rheum Dis Clin North Am. 2004;30:69-95. (Pubitemid 38234769)
18. Kim SF, Huri DA, Snyder SH. Inducible nitric oxide synthase binds, S-nitrosylates, and activates cyclooxygenase-2. Science. 2005;310:1966-70. (Pubitemid 43005992)
19. Zhou G, Ge S, Liu D, et al. Atorvastatin reduces plaque vulnerability in an atherosclerotic rabbit model by altering the 5- lipoxygenase pathway. Cardiology. 2010;115:221-8.
20. Poeckel D, Funk CD. The 5-Lipoxygenase/Leukotriene Pathway in Preclinical Models of Cardiovascular Disease. Cardiovasc Res. 2010;86:243-53. This article describes the role of 5-lipoxygenase and the leukotriene pathway in various models of atherosclerosis.
21. Laaksonen R, Janis MT, Oresic M. Lipidomics-based safety biomarkers for lipid-lowering treatments. Angiology. 2008;59:65S- 8S.
22. Laaksonen R, Katajamaa M, Paiva H, et al. A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin-induced changes in muscle. PLoS One. 2006;1:e97.
23. Gronroos E, Andersson T, Schippert A, et al. Leukotriene D4- induced mobilization of intracellular Ca2+ in epithelial cells is critically dependent on activation of the small GTP-binding protein Rho. Biochem J. 1996;316(Pt 1):239-45.
24. Zhao SP, Zhang DQ. Atorvastatin reduces interleukin-6 plasma concentration and adipocyte secretion of hypercholesterolemic rabbits. Clinica Chimica Acta. 2003;336:103-8.
25. Koch W, Hoppmann P, Mueller JC, et al. No association of polymorphisms in the gene encoding 5-lipoxygenase-activating protein and myocardial infarction in a large central European population. Genet Med. 2007;9:123-9.
26. Lemaitre RN, Rice K, Marciante K, et al. Variation in eicosanoid genes, non-fatal myocardial infarction and ischemic stroke. Atherosclerosis. 2009;204:e58-63.
27. Gomez-Hernandez A, Sanchez-Galan E, Ortego M, et al. Effect of intensive atorvastatin therapy on prostaglandin E2 levels and metalloproteinase-9 activity in the plasma of patients with non- ST-elevation acute coronary syndrome. Am J Cardiol. 2008;102: 12-8.